Public Profile

Mylan, Inc.

Mylan, Inc., a global leader in the pharmaceutical industry, is headquartered in the United States and operates extensively across North America, Europe, and Asia. Founded in 1961, Mylan has established itself as a key player in generic and specialty medications, focusing on providing high-quality, affordable healthcare solutions. The company is renowned for its extensive portfolio, which includes a wide range of generic and branded drugs, biosimilars, and over-the-counter products. Mylan's commitment to innovation and accessibility sets it apart in the competitive landscape, enabling it to serve millions of patients worldwide. With a strong market position, Mylan has achieved significant milestones, including strategic mergers and acquisitions that have expanded its global reach and product offerings. The company's dedication to improving health outcomes continues to drive its success in the ever-evolving pharmaceutical sector.

DitchCarbon Score

How does Mylan, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

32

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Mylan, Inc.'s score of 32 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.

0%

Let us know if this data was useful to you

Mylan, Inc.'s reported carbon emissions

Mylan, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor does it specify any reduction targets or initiatives. Without specific emissions figures or commitments, it is challenging to assess the company's climate impact or its strategies for addressing carbon emissions. In the pharmaceutical industry, companies are increasingly focusing on sustainability and climate commitments, but Mylan's current stance on these issues remains unclear.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Mylan, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Mylan, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Mylan, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Amgen

US
Chemicals nec
Updated 15 minutes ago

Hikma Labs Inc.

US
Pharmaceutical Preparation Manufacturing
Updated about 8 hours ago

Genentech

US
Pharmaceutical Preparation Manufacturing
Updated about 8 hours ago

Genentech USA, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated about 8 hours ago

Pfizer

US
Pharmaceutical Preparation Manufacturing
Updated about 8 hours ago

ADVANZ PHARMA Corp. Limited

GB
Pharmaceutical Preparation Manufacturing
Updated about 8 hours ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers